Biotech Startup Yumanity Therapeutics Launched To Develop New Therapies for Neurodegenerative Diseases Caused by Protein Misfolding

Biotech Startup Yumanity Therapeutics Launched To Develop New Therapies for Neurodegenerative Diseases Caused by Protein Misfolding
Biotech industry veteran Tony Coles, M.D. has launched a new startup — Cambridge, Massachusetts-based Yumanity Therapeutics. Founded in December 2014, the new company’s central focus is on drug discovery for diseases caused by a DNA anomaly called “protein misfolding.” Yumanity Therapeutics’ founders include by Dr. Coles, who is chairman and chief executive officer, and scientific

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *